TScan Therapeutics

Name

TScan Therapeutics

Legal name

TScan Therapeutics, Inc.

Website

https://tscan.com

Company type

Public

Founded year

2018

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

akta.pro secondary industry

Bone Marrow & Stem Cell Transplant (BMT/HSCT) (HLAKAFAI)

Keywords

• TCR-T cell therapy
• Cancer immunotherapy
• Allogeneic cell therapy
• Hematologic malignancy treatment
• TCR discovery platform

Headquarters

HQ city

Waltham

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Collaboration Revenue: Revenue from multi-year collaboration agreement with Amgen for TargetScan platform utilization in Crohn's disease research. Revenue of $1.0M in Q1 2026, down from $2.2M in Q1 2025 due to timing of research activities.
2. Future Product Revenue: Pre-revenue stage company. Anticipated future revenue from commercialization of TCR-T therapy candidates, primarily TSC-101 for AML and MDS.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

TScan Therapeutics is a clinical-stage biotechnology company developing allogeneic, donor-derived T cell receptor-engineered T cell (TCR-T) therapies to treat patients with hematologic malignancies and solid tumors. Its lead candidate TSC-101 targets the HA-2 antigen for HLA-A*02:01-positive AML and MDS patients undergoing allogeneic hematopoietic cell transplantation to eliminate residual disease and prevent relapse, supported by the proprietary TargetScan genome-wide TCR epitope discovery platform.

Product overview

TScan Therapeutics is a clinical-stage biotechnology company developing a pipeline of T cell receptor-engineered T cell (TCR-T) therapies for cancer treatment. The company's core product is TSC-101, an allogeneic TCR-T therapy targeting the HA-2 antigen for AML and MDS patients undergoing transplantation. Additional pipeline products include TSC-102, targeting CD45 for multiple HLA types. The technology foundation is the TargetScan discovery platform, which enables genome-wide identification of T cell epitopes. The company is also developing an in vivo engineering platform for off-the-shelf, multiplexed TCR-T therapies targeting solid tumors. TScan operates primarily in hematologic malignancies while maintaining programs in solid tumors and autoimmunity.

Differentiator

Problem solved

Functional benefit

Products and services

• TSC-101 Lead allogeneic, donor-derived TCR-T therapy candidate targeting the HA-2 antigen for HLA-A*02:01-positive patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) undergoing allogeneic hematopoietic cell transplantation; designed to eliminate residual disease and prevent relapse.
• TSC-102 Allogeneic, donor-derived TCR-T therapy candidates targeting epitopes derived from CD45 for patients with HLA types A*01:01, A*03:01, and A*24:02; designed to eliminate residual cancer cells and prevent relapse in patients undergoing HCT for hematologic malignancies and to expand the addressable patient population beyond HLA-A*02:01.
• TargetScan Discovery Platform Proprietary genome-wide target discovery platform that enables rapid identification of peptide antigen targets of T cell receptors; used internally to discover TCR/target pairs for TScan's pipeline and licensed to partners (e.g., Amgen) for T cell antigen identification in indications such as Crohn's disease.
• In Vivo-Engineered TCR-T Platform An in vivo engineering platform for delivering off-the-shelf, multiplexed TCR-T therapy for solid tumors, intended as a cost-efficient approach to treat heterogeneous solid tumor malignancies.

Quantifiable outcome

• 93% response rate in Phase 1 ALLOHA trial Cohort C
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered core.

• CellarescoreTechnology or Integration · 3 June 2026Agreement to evaluate automated clinical manufacturing of TSC-101 using Cellares' fully automated Cell Shuttle and Cell Q platforms. Aims to reduce process variability and enable scalable, cost-efficient production as TScan prepares for pivotal trial expected Q2 2026.
• AmgencoreStrategic or Co-development Partner · 1 May 2023Multi-year collaboration initiated May 2023 leveraging TScan's TargetScan platform to identify antigens recognized by T cells in Crohn's disease patients. Amgen retains all global development and commercial rights to discovered targets. TScan receives research funding and potential milestones.

Scale indicators8 records

Recent moves3 records

Direct peers

• Adaptimmune Therapeutics: Clinical-stage biotech developing SPEAR T-cell receptor (TCR-T) therapies for solid tumors. Adaptimmune is the most directly comparable TCR-T competitor, with an FDA-approved product (TECELRA) and overlapping platform approach to engineered T-cell therapy.
• Immatics: Clinical-stage biotech developing TCR-based immunotherapies for solid tumors using a proprietary target discovery platform (XPRESIDENT). Immatics is highly comparable given its TCR-T focus and discovery-platform business model similar to TScan's TargetScan.
• Iovance Biotherapeutics: Commercial-stage cell therapy company with FDA-approved lifileucel (Amtagvi) for solid tumors. Iovance is a direct peer in autologous cell therapy manufacturing and oncology commercialization, with overlapping clinical and operational challenges to TScan's TCR-T approach.
• Allogene Therapeutics: Clinical-stage biotech developing allogeneic (off-the-shelf) CAR-T cell therapies for hematologic and solid tumors. Allogene's allogeneic platform addresses the same scalability and HLA-matching challenges TScan faces with its donor-derived TCR-T approach.
• Precision BioSciences: Clinical-stage biotech developing allogeneic CAR-T therapies using its ARCUS gene editing platform. Precision is a peer in engineered cell therapy development with similar allogeneic manufacturing complexity and oncology focus.
• Caribou Biosciences: Clinical-stage biotech developing allogeneic CAR-T cell therapies using CRISPR-based gene editing. Caribou is a peer in allogeneic cell therapy development targeting hematologic malignancies with comparable manufacturing and clinical execution requirements.
• Cellectis: Clinical-stage biotech developing gene-edited allogeneic CAR-T cell therapies (UCART platform). Cellectis is a peer in allogeneic engineered cell therapy with similar TCR/CAR hybrid approaches and TALEN-based gene editing for cell therapy manufacturing.

Broad incumbents

• CRISPR Therapeutics: Commercial-stage gene editing company with FDA-approved Casgevy (exa-cel) for sickle cell disease and beta-thalassemia. CRISPR Therapeutics is a broad incumbent in gene-edited cell therapy with established manufacturing infrastructure and overlapping cell therapy talent pool (TScan CMO previously worked there).

Emerging players

• Fate Therapeutics: Clinical-stage biotech developing iPSC-derived off-the-shelf NK and T-cell therapies. Fate represents an emerging modality that could compete with TScan's donor-derived TCR-T if iPSC-derived approaches achieve commercial viability.
• Vor Biopharma: Clinical-stage biotech focused on engineered hematopoietic cell transplants for AML and other hematologic malignancies. Vor Biopharma addresses the same post-transplant relapse setting that TScan targets with TSC-101, representing an alternative modality competing for the same clinical opportunity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/tscanrx
• LinkedInlinkedin.com/company/tscan-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds8 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TScan Therapeutics